Table 1. Cell cycle analysis at 48 hours of treatment.
| LnCap tumor cells | |||
|---|---|---|---|
| Treatment Groups | Phases of cell cycle | ||
| G0/G1 | S | G2/M | |
| Regular Medium with 10% FBS | 63%+/-10% | 22%+/- 6% | 15%+/- 4% |
| Continuous T treatment (3.3 nM) | 64%+/-8% | 16%+/-8% | 22% +/-6% |
| Continuous T treatment (5.2 nM) | 69%+/- 4% | 16%+/- 3% | 15%+/-8% |
| Continuous T treatment (17.2 nM) | *72%+/-4% | 18%+/- 5% | 10%+/-2% |
| Pulsed T treatment (5.2 nM) | *89% +/-12% | 6%+/- 3% | 5%+/-2% |
| Pulsed T treatment (17.2 nM) | *91%+/-8% | 4%+/- 2% | 5%+/-3% |
*P<0.05 vs 10% FBS. | |||
| CW22RV1 tumor cells | |||
|---|---|---|---|
| Treatment Groups | Phases of cell cycle | ||
| G0/G1 | S | G2/M | |
| Regular Medium with 10% FBS | 58% +/-6% | 22% +/- 3% | 20% +/- 5% |
| Continuous T treatment (3.3 nM) | 60% +/- 8% | 15% +/-6% | 23%+/-3% |
| Continuous T treatment (5.2 nM) | 61% +/- 5% | 24% +/- 4% | 16% +/- 5% |
| Continuous T treatment (17.2 nM) | *67% +/-2% | 20% +/- 6% | 13% +/- 3% |
| Pulsed T treatment (5.2 nM) | *82% +/-10% | 22% +/- 7% | 5%/3% |
| Pulsed T treatment (17.2 nM) | *83% +/-9% | 14% +/- 4% | 5% +/-2% |
*P<0.05 vs 10% FBS.